TTP273 is an oral, small molecule GLP-1R agonist with best-in-class
potential
Topline results are expected at the end of 2016
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced the enrollment of the first patients in the Company’s Phase 2
LOGRA (aLlosteric Oral Glp1 Receptor Agonist)
study, a randomized, double-blind, placebo-controlled, parallel group
trial of TTP273. TTP273 is an oral, small molecule GLP-1R agonist with
best-in-class potential.
The previous Phase 1b trial of TTP273 demonstrated robust effects on
postprandial and fasting glucose. All doses of TTP273 were safe and well
tolerated with no serious adverse events or evidence of gastrointestinal
side effects compared to placebo.
“Earlier studies of this compound showed that TTP273 has the potential
to provide enhanced glycemic control and weight loss without the burden
of injections or gastrointestinal side effects seen with GLP-1 biologic
agents,” said Steve Holcombe, President and CEO of vTv. “TTP273 is just
one of two diabetes treatments in our pipeline reading out this year
with our best-in-class orally administered Glucokinase Activator,
TTP399, expected to report Phase 2 results in mid-2016.”
The LOGRA study is assessing the safety and efficacy of TTP273 in Type 2
diabetic patients on stable doses of metformin. The study’s primary
endpoint is change in baseline in HbA1c at 3 months, with secondary
endpoints including body weight, plasma glucose, lipids insulin,
lactate, C-peptide, glucagon and GLP. The Company anticipates enrolling
156 patients at 26 clinical trial sites throughout the United States.
Topline results are expected at the end of 2016.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
About Type 2 Diabetes
Type 2 diabetes is the body’s inability to properly use insulin to
control sugar in the bloodstream. It is the most common type of diabetes
(representing 90 to 95% of diabetes patients), imposing a growing burden
on healthcare systems globally. The goal of maintaining HbA1c levels
below 7.0% is elusive for patients with this life-long disease. In
addition to unregulated glucose, diabetics commonly have a variety of
co-morbidities, including heart disease, stroke, high blood pressure,
blindness, kidney disease, amputations, dental disease, and central and
peripheral nervous system impairment.
About the LOGRA Study
The LOGRA Phase 2 study will evaluate TTP273, which would be an orally
bioavailable, potent, non-peptide agonist of GLP-1R for the treatment of
type 2 diabetes. This molecule is the second generation from a
path-finder molecule TTP054, and it is anticipated to provide enhanced
glycemic control, weight loss and an attractive safety profile for the
treatment of Type 2 diabetes. The completed Phase 1b trial in TTP273
demonstrated robust effects on postprandial & fasting glucose.
The LOGRA study is expected to read out in late-2016.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Registration Statement on Form S-1 and our other filings with the
SEC. These forward-looking statements reflect our views with respect to
future events as of the date of this release and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements represent
our estimates and assumptions only as of the date of this release and,
except as required by law, we undertake no obligation to update or
review publicly any forward-looking statements, whether as a result of
new information, future events or otherwise after the date of this
release. We anticipate that subsequent events and developments will
cause our views to change. Our forward-looking statements do not reflect
the potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of our
forward-looking statements by these cautionary statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005208/en/
Copyright Business Wire 2016